IDIBELL on the media
Discovered a molecule that regulates the development of cancer in a variety of human tumors
Researchers from IDIBELL-ICO and IJC discover that a non-coding region of the genome originates a key molecule for the proliferation of tumors in breast cancer and some types of sarcoma
“We save lives” looks for heroes at Bellvitge’s ‘festa major’
On the occasion of the ‘festa major’ of Bellvitge, an annual celebration which takes place in this district of L’Hospitalet from September 7 to 15, researchers of the Oncobell program of the Bellvitge Biomedical Research Institute (IDIBELL) present the #josalvovides fundraising campaign for cancer research from an informative stand. This action, which has been possible […]
An IDIBELL study offers new possibilities for personalized medicine to treat a prevalent type of liver cancer
Results show that in order to treat patients efficiently, it is necessary to know the specific molecular characteristics of their cancer, such as TGF-β and EGF receptor expression levels
Apathy as an indicator of progression in Huntington’s disease
IDIBELL-UB researchers associate changes in white matter connectivity in different subtypes of apathy, one of the most common psychiatric syndromes in Huntington’s disease (HD)
Higher consumption of soft drinks linked with an increased risk of mortality
This is the main highlight of a study published today in JAMA Internal Medicine, based on a population of about 452,000 people of both genders from 10 European countries followed over a period of 16 years.
Professional-guided online cancer communities improve well-being, quality of life and reduce emotional distress and the risk of hospitalizations
Digital transformation and online resources are changing the relationship between healthcare professionals and their patients, and the way medical care is provided. The change from a traditional paternalistic model of medical care to a relational one, focused on the needs of patients and their families, promotes the empowerment of the user, responsibility for their illness, […]
Researchers from the IDIBELL and the University of Barcelona describe a new treatment that could cope with two bone diseases
The study describes the ability of a PI3-kinase inhibitor to combat Heterotopic Ossification and Fibrodysplasia Ossificans Progressiva in murine preclinical models
EXTENDED DEADLINE — Expression of Interest (EoI) for Collaborative Projects on Regenerative Medicine
1.- Background The Centre for Regenerative Medicine of Barcelona (CMR[B]), together with the Biomedical Research Institute of Bellvitge (IDIBELL), at the behest of the Catalan Government(1), have launched the Program for advancing the Clinical Translation of Regenerative Medicine of Catalonia – P-CMR[C]. The fundamental mission of the P-CMR[C] is to advance the implementation of regenerative medicine strategies by conducting research […]
